Background
Etanercept is the active ingredient in Enbrel, one of the world’s best-selling biologic drugs, used to treat rheumatoid arthritis, psoriasis, and other autoimmune conditions. The technology underlying etanercept was developed by multiple parties: Immunex Corporation developed the protein construct, while Roche held patents on key TNF receptor components. To commercialize Enbrel, Immunex entered into a license agreement with Roche under which Roche granted Immunex rights to practice its patents relating to TNFR fusion proteins.
Sandoz sought to market a biosimilar version of Enbrel. In litigation, Sandoz argued that Immunex’s patents were invalid for obviousness-type double patenting (ODP) — the doctrine that prevents an inventor from extending patent protection on the same or obvious variant of an invention through a second patent. Sandoz contended that Immunex’s patents and Roche’s licensed patents were “commonly owned” because Roche had licensed all substantial rights to Immunex, making the license effectively an assignment. If the patents were commonly owned, ODP would apply and could invalidate Immunex’s claims.
The District of New Jersey disagreed with Sandoz and upheld the patents. Sandoz appealed to the Federal Circuit.
The Court’s Holding
The Federal Circuit affirmed. Writing for the majority, Judge Lourie held that the Roche–Immunex license was not an effective assignment because Roche retained several significant rights over the licensed patents: (1) Roche retained a secondary right to sue if Immunex chose not to enforce the patents; (2) Roche retained entitlement to the entirety of any damages or profits recovered in infringement litigation; and (3) Roche retained other meaningful controls over the patents. These retained rights, the court held, established that Roche never transferred “all substantial rights” to Immunex.
Because Roche retained substantial rights, there was no effective common ownership of the Roche and Immunex patents, and the ODP doctrine — which presupposes a single inventor or commonly owned group of patents — did not apply. The court distinguished cases where a licensor retained only nominal rights from those, like this one, where the licensor’s retained rights materially affected who controlled enforcement and benefited from the patents.
Judge Newman dissented, arguing that the majority’s approach created an easily manipulated escape hatch from ODP by allowing licensors to draft agreements that retain sufficient formal rights to defeat common ownership while still effectively transferring control of the patent portfolio.
Key Takeaways
- Obviousness-type double patenting requires common ownership; a licensor and licensee do not hold patents in common if the licensor retains substantial rights such as secondary enforcement authority and exclusive entitlement to damages.
- A patent license is not an effective assignment — and thus cannot create common ownership for ODP purposes — if the licensor retains meaningful control rights over the patents.
- Drafting patent license agreements with retained rights (secondary enforcement rights, retained damages entitlement) can defeat ODP claims that would otherwise apply between the licensor’s and licensee’s patents.
- Biosimilar and generic challengers relying on ODP as an invalidity theory must carefully evaluate whether the license relationship truly resulted in an effective assignment of all substantial rights.
Why It Matters
The Immunex v. Sandoz decision has significant implications for the biopharmaceutical industry, where complex licensing arrangements among multiple parties are common. The ruling confirms that careful structuring of patent licenses — specifically, retaining meaningful rights at the licensor level — can shield a portfolio from ODP attacks that might otherwise shorten patent life on blockbuster drugs. For Enbrel, this meant continued protection against biosimilar competition through the full patent term.
More broadly, the case illustrates how ODP doctrine intersects with the economics of patent licensing. Companies that in-license foundational technology while developing their own improvements must assess whether their license structure could create ODP vulnerability down the line. The decision signals that sophisticated licensors and licensees can contractually preserve patent independence — and defeat ODP claims — through careful allocation of enforcement rights and damage entitlements in the license agreement.